Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-12-04
2010-02-09
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S415000, C544S135000, C548S159000
Reexamination Certificate
active
07659269
ABSTRACT:
Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.
REFERENCES:
patent: 3557142 (1971-01-01), Bell
patent: 4251528 (1981-02-01), Brittain et al.
patent: 4283539 (1981-08-01), Schnur
patent: 4438126 (1984-03-01), Ueda et al.
patent: 4868301 (1989-09-01), Mylari et al.
patent: 4939140 (1990-07-01), Larson et al.
patent: 4960785 (1990-10-01), Howard et al.
patent: 5064852 (1991-11-01), Howard et al.
patent: 5236945 (1993-08-01), Mylari et al.
patent: 5304557 (1994-04-01), Mylari
patent: 5312829 (1994-05-01), Okada et al.
patent: 5330997 (1994-07-01), Mylari et al.
patent: 5332755 (1994-07-01), Butler et al.
patent: 5641800 (1997-06-01), Bach et al.
patent: 5700819 (1997-12-01), Aotsuka et al.
patent: 5744488 (1998-04-01), Cross et al.
patent: 6214991 (2001-04-01), Jones et al.
patent: 6426344 (2002-07-01), Jones et al.
patent: 6521659 (2003-02-01), Sredy et al.
patent: 6730794 (2004-05-01), Jones et al.
patent: 6964980 (2005-11-01), Sredy et al.
patent: 7105514 (2006-09-01), Jones et al.
patent: 7304079 (2007-12-01), Jones et al.
patent: 0 054 417 (1982-06-01), None
patent: 0 199 543 (1986-10-01), None
patent: 0 222 576 (1987-05-01), None
patent: 0 401 981 (1990-12-01), None
patent: 0 539 117 (1993-04-01), None
patent: 0 624 369 (1994-11-01), None
patent: 0 705 607 (1996-04-01), None
patent: 714 893 (1996-06-01), None
patent: 2 647 676 (1990-12-01), None
patent: 09 165371 (1997-06-01), None
patent: WO 93/12786 (1993-07-01), None
patent: WO 95/06046 (1995-03-01), None
patent: WO 95/31453 (1995-11-01), None
patent: WO 96/03376 (1996-02-01), None
patent: WO 96/26207 (1996-08-01), None
patent: WO 99/50268 (1999-10-01), None
Patini, et al., Chem Rev., 1996, 96(8), pp. 3147-3176, specifically pp. 3152-3153.
Chemical Abstracts, vol. 125, No. 10615, 1996.
Cross et al., “Selective Thromboxane Synthetase Inhibitors. 2. 3-(1H-Imidazol-1-ylmethyl)-2-methyl-1H-indole-1- propanoic Acid and Analogues”, American Chemical Society, (1986), pp. 342-346.
Doebel et al., “Derivatives of Indole-1-acetic Acid as Antiinflammatory Agents”, Journal of Medicinal Chemistry, (1972), vol. 15, No. 10, pp. 1081-1082.
Kador et al., “Aldose Reductase Inhibitors: A Potential New Class of Agents for the Harmacological Control of Certain Diabetic Complications”, Journal of Medicinal Chemistry (American Chemical Society), (1985), vol. 28, No. 7, pp. 841-849.
Kador et al., “Pharmacophor Requirements of the Aldose Reductase Inhibitor Site”, Molecular Pharmacology, (1983), vol. 24, pp. 521-531.
Aotsuka et al., “Benzothiazol-2-Ylcarboxylic Acids with Diverse Spacers: A Novel Class of Potent, Orally Active Aldose Reductase Inhibitors”, Biorganic & Medicinal Chemistry Letters, (1997), vol. 7, No. 13, pp. 1677-1682.
Humber, Ph.D., L., “The Medicinal Chemistry of Aldose Reductase Inhibitors, Chapter 5”, Aldose Reductase Inhibition (Biomedical Information Corporation), (1987), pp. 326-353.
Larson et al., “Medicinal Chemistry of Aldose Reductase Inhibitors”, Medicinal Research Reviews, (1988), vol. 8, No. 2, pp. 159-186.
Dvornik D., “Inhibitors of Aldo Reductase, Chapter 16”, Design of Enzyme Inhibitors as Drugs, (1994), vol. 2, pp. 710-738.
Matassa et al., “Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure/Activity Relationships of 1,3,5-Substituted Indoles and Indazoles”, J. Med. Chem., (1990), vol. 33, pp. 1781-1790.
Mylar et al., “Novel, Potent Aldose Reductase Inhibitors: 3,4-Dihydro-4-oxo-3[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazine-acetic Acid (Zopolrestat) and Congeners”, J. Med. Chem., (1991), vol. 34, No. 1, pp. 108-122.
Aotsuka et al., “Novel and Potent Aldose Reductase Inhibitors: 4-Benzyl- and 4-(Benzothiazol-2-ylmethyl)-3,4- dihydro-3-oxo-2H-1,4-benzothiazine-2-acetic Acid Derivatives”, Chem. Pharm. Bull., (1994), vol. 42, No. 6, pp. 1264-1271.
International Search Report for PCT/US1999/28483 dated Sep. 7, 2000.
International Search Report for PCT/US1999/07116 dated Nov. 4, 1999.
Dickinson, Roger P. et al., “Thromboxane Modulating Agents. 2. Thromboxane Receptor Antagonists Derived from teh Thromboxane Synthase Inhibitor Dazmegrel”, Bioorganic & medicinal Chemistry Letters, vol. 6, No. 14, pp. 1691-1696 (1996).
Whitehead, Calvert W., “Effect of Lipophilic Substituents on Some Biological Properties of Indoles”, Journal of Medicinal Chemistry, 1974, vol. 17, No. 12, pp. 1298-1304.
Gunn David
Jones John
Jones Michael
Van Zandt Michael
Chung Susannah
McDonnell Boehnen & Hulbert & Berghoff LLP
Shameem Golam M. M.
The Institute for Pharmaceutical Discovery LLC
LandOfFree
Substituted indolealkanoic acids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted indolealkanoic acids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted indolealkanoic acids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4201678